3SBio, Inc. 1530
HKEX · Hong Kong SAR China · Health Technology
HKD 16.57+0.65 (+4.08%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
HANGZHOU, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- MindRank AI Ltd. ("MindRank") today announced that it has entered into a strategic commercialization agreement with Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. ("Mandi") and Zhejiang Wansheng Pharmaceutical Co., Ltd. ("Wansheng"), both subsidiaries of 3SBio Inc. (01530.HK) group, for MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist in a pivotal Phase 3 trial in China for obesity and overweight. The collaboration covers ma
3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing a year-over-year growth of 3.9%. Net profit attributable to equity holders of the Company reached RMB 1.15 billion, and adjusted operating net profit attributable to shareholders of the parent stood at RMB 1.44 billion, up 26.5% year-over-year. R&D expenses amounted to RMB 680 million, an increase of 24.9% year-over-year. The Company'
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.